Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q2 2022 · 10-Q
Revenue$140.87M$140.87M+5.5% vs Q2 2021 Net Income-$24.01M-$24.01MN/M vs Q2 2021 EPS Diluted-$0.23-$0.23N/M vs Q2 2021 Gross Profit$112,363,000+7.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$15,762,000−39.8% Free Cash Flowderived$11,631,000−50.6% Margins · derivedGross margin79.8%+1.2 pt vs Q2 2021
Operating margin-15.0%−5.8 pt vs Q2 2021
Net margin-17.0%−6.1 pt vs Q2 2021
ended Jun 30, 2022 · filed Jul 28, 2022 · 28 d after period end